Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1656 related articles for article (PubMed ID: 24915421)

  • 1. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
    Chen YC; Huang WJ; Hsu JL; Yu CC; Wang WT; Guh JH
    Prostate; 2013 Sep; 73(12):1270-80. PubMed ID: 23813634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
    Namdar M; Perez G; Ngo L; Marks PA
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
    Cincinelli R; Musso L; Artali R; Guglielmi MB; La Porta I; Melito C; Colelli F; Cardile F; Signorino G; Fucci A; Frusciante M; Pisano C; Dallavalle S
    PLoS One; 2018; 13(10):e0205018. PubMed ID: 30300374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
    Lee HY; Lee JF; Kumar S; Wu YW; HuangFu WC; Lai MJ; Li YH; Huang HL; Kuo FC; Hsiao CJ; Cheng CC; Yang CR; Liou JP
    Eur J Med Chem; 2017 Jan; 125():1268-1278. PubMed ID: 27886544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
    Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
    Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
    Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
    J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
    Zhang X; Bao B; Yu X; Tong L; Luo Y; Huang Q; Su M; Sheng L; Li J; Zhu H; Yang B; Zhang X; Chen Y; Lu W
    Bioorg Med Chem; 2013 Nov; 21(22):6981-95. PubMed ID: 24095018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
    Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
    Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
    Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
    Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.